The E-box transcription factor TCF4 is a lineage-survival oncogene in BPDCN
BET inhibitors are highly toxic to BPDCNs, both in vitro and in vivo
A druggable TCF4/BRD4 transcriptional network sustains malignancy in BPDCN
BET inhibitors should be explored for the clinical management of BPDCN